| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/30/2013 | CA2856759A1 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
| 05/30/2013 | CA2856708A1 Antibacterial tylosin derivatives and methods for their preparation |
| 05/30/2013 | CA2856706A1 Method for producing substituted 5-fluoro-1h-pyrazolopyridines |
| 05/30/2013 | CA2856696A1 Antiviral formulations |
| 05/30/2013 | CA2856692A1 Imatinib solid dosage forms reconstituted just before use |
| 05/30/2013 | CA2856680A1 Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder |
| 05/30/2013 | CA2856672A1 Pharmaceutical composition useful for prevention of adhesion or for hemostasis |
| 05/30/2013 | CA2856522A1 Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa) |
| 05/30/2013 | CA2856520A1 Natural combination hormone replacement formulations and therapies |
| 05/30/2013 | CA2856507A1 Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
| 05/30/2013 | CA2856506A1 Method for treating hepatitis c virus infection using quercetin-containing compositions |
| 05/30/2013 | CA2856501A1 A drug carrier with chelating complex micelles and the application thereof |
| 05/30/2013 | CA2856386A1 Heterocyclic inhibitors of glutaminase |
| 05/30/2013 | CA2856379A1 Small molecule enhancer for dendritic cell cancer vaccines |
| 05/30/2013 | CA2856357A1 3-cyanoaryl-1h-pyrrolo[2,3-b]pyridine derivatives |
| 05/30/2013 | CA2856306A1 Selective kinase inhibitors |
| 05/30/2013 | CA2856301A1 Pyrazine kinase inhibitors |
| 05/30/2013 | CA2856102A1 Tetrahydrocannabivarin (thcv) for use in the protection of pancreatic islet cells |
| 05/30/2013 | CA2855980A1 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| 05/30/2013 | CA2855854A1 L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders |
| 05/30/2013 | CA2855446A1 Thienopyrimidine inhibitors of atypical protein kinase c |
| 05/30/2013 | CA2854649A1 Solid state forms of vilazodone and vilazodone hydrochloride |
| 05/30/2013 | CA2854569A1 Novel pyrrolidine derivatives as inhibitors of cathepsin |
| 05/30/2013 | CA2854252A1 1,4-dihydropyridine derivatives with hsp modulating activity |
| 05/30/2013 | CA2854039A1 Isoxazole treatments for diabetes |
| 05/30/2013 | CA2853764A1 Immediate release abuse deterrent tablet |
| 05/30/2013 | CA2851387A1 Cysteamine and/or cystamine for treating ischemic injury |
| 05/30/2013 | CA2850697A1 [1, 2, 3]triazolo [4 , 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists |
| 05/30/2013 | CA2846496A1 Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| 05/29/2013 | EP2597098A1 (7h-pyrrolo [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation |
| 05/29/2013 | EP2597097A1 Substituted indoles, antiviral active component, method for producing and using same |
| 05/29/2013 | EP2597095A1 Fused heterocyclic compound and application thereof |
| 05/29/2013 | EP2597093A1 Benzofuranone compound and pharmaceutical composition containing same |
| 05/29/2013 | EP2597091A1 Antitumoral Compounds |
| 05/29/2013 | EP2597090A1 Crystalline dapagliflozin hydrate |
| 05/29/2013 | EP2597089A1 Tricyclic heterocyclic compounds |
| 05/29/2013 | EP2597088A1 P2x4 receptor antagonist |
| 05/29/2013 | EP2597087A1 Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors |
| 05/29/2013 | EP2597086A1 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same |
| 05/29/2013 | EP2597085A1 Organic compounds |
| 05/29/2013 | EP2597084A1 N-hydroxyformamide derivative and pharmaceutical containing same |
| 05/29/2013 | EP2597083A2 Selective hydroxamate based MMP inhibitors |
| 05/29/2013 | EP2596796A1 Complex obtained from hyaluronic acid or a salt thereof and chondroitin sulphate mixtures |
| 05/29/2013 | EP2596795A1 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
| 05/29/2013 | EP2596794A1 Method for treating liver diseases of various origins |
| 05/29/2013 | EP2596793A1 Quinoline derivatives as PI3 kinase inhibitors |
| 05/29/2013 | EP2596792A1 Stable solid preparations |
| 05/29/2013 | EP2596791A1 Stable solid preparations |
| 05/29/2013 | EP2596790A1 Pim kinase inhibitors and methods of their use |
| 05/29/2013 | EP2596789A1 Oral medicinal composition for patients undergoing peritoneal dialysis and method for using same |
| 05/29/2013 | EP2596788A1 Tacrolimus-containing oil-in-water type creamy composition |
| 05/29/2013 | EP2596787A1 New use of hesperetin |
| 05/29/2013 | EP2596786A1 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
| 05/29/2013 | EP2596785A1 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| 05/29/2013 | EP2596784A1 Tapentadol compositions |
| 05/29/2013 | EP2596704A1 Increasing the bioavailability of hydroxycinnamic acids |
| 05/29/2013 | EP2596366A1 Combination therapy with mdm2 and efgr inhibitors |
| 05/29/2013 | EP2596013A1 Nkx2.2 inhibitors as drugs |
| 05/29/2013 | EP2596005A2 Antiviral agents |
| 05/29/2013 | EP2595993A2 Tricyclic proteasome activity enhancing compounds |
| 05/29/2013 | EP2595991A2 METHODS AND COMPOSITIONS FOR INHIBITING THE NUCLEAR FACTOR kB PATHWAY |
| 05/29/2013 | EP2595989A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| 05/29/2013 | EP2595988A1 Tricyclic compounds and methds of making and using same |
| 05/29/2013 | EP2595987A1 New aminopyrazoloquinazolines |
| 05/29/2013 | EP2595983A1 2,3,5-trisubstituted thiophene compounds and uses thereof |
| 05/29/2013 | EP2595982A1 Protein kinase c inhibitors and uses thereof |
| 05/29/2013 | EP2595977A1 Process for preparing benzofuran derivatives substituted at position 5 |
| 05/29/2013 | EP2595975A2 Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| 05/29/2013 | EP2595972A1 Tricyclic lactones for treatment of cancer |
| 05/29/2013 | EP2595971A1 Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| 05/29/2013 | EP2595970A1 Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics |
| 05/29/2013 | EP2595969A1 Substituted 3-phenyl-1,2,4-oxadiazole compounds |
| 05/29/2013 | EP2595968A1 Novel process for preparation of linezolid and its novel intermediates |
| 05/29/2013 | EP2595964A1 Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them |
| 05/29/2013 | EP2595959A1 Sulfonyl compounds which modulate the cb2 receptor |
| 05/29/2013 | EP2595957A1 Pyridin- 2 - yl sulfanyl acid esters and process for the preparation thereof |
| 05/29/2013 | EP2595953A1 Process for the synthesis of isothiocyanates and derivatives thereof and uses of same |
| 05/29/2013 | EP2595952A1 Agonists of gpr40 |
| 05/29/2013 | EP2595762A1 Method of coating an inorganic substrate with a stable organic layer |
| 05/29/2013 | EP2595664A2 Modulation of nuclear-retained rna |
| 05/29/2013 | EP2595663A2 Modulation of dystrophia myotonica-protein kinase (dmpk) expression |
| 05/29/2013 | EP2595660A2 Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| 05/29/2013 | EP2595648A2 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity |
| 05/29/2013 | EP2595643A1 Anti-viral properties of aloe vera and acquired immune deficiency syndrome (aids) treatment |
| 05/29/2013 | EP2595642A2 Compositions comprising derivatives of essential oil compounds and use in personal care products |
| 05/29/2013 | EP2595641A1 Use of a fermented soy extract for manufacture of a prebiotic composition |
| 05/29/2013 | EP2595640A1 Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha |
| 05/29/2013 | EP2595636A2 Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution |
| 05/29/2013 | EP2595635A1 Polydeoxyribonucleotides (pdrns) for use in the treatment of metabolic and/or lactic acidosis and polydeoxyribonucleotide-based compositions for the aforesaid use |
| 05/29/2013 | EP2595634A1 Antifungal and antiparasitic polyene macrolides |
| 05/29/2013 | EP2595633A2 Methods of intravenous administration of glyburide and other drugs |
| 05/29/2013 | EP2595632A1 Noribogaine compositions |
| 05/29/2013 | EP2595631A2 Pharmaceutical compositions of cefditoren pivoxil |
| 05/29/2013 | EP2595630A1 Use of a2b adenosine receptor antagonists for treating pulmonary hypertension |
| 05/29/2013 | EP2595629A1 Pure erlotinib |
| 05/29/2013 | EP2595628A1 Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| 05/29/2013 | EP2595627A1 Use of uleine for the prevention and/or the treatment of infectious diseases |
| 05/29/2013 | EP2595626A1 Combination of siloxane and active ingredient for treating dental disorder |
| 05/29/2013 | EP2595625A1 Pharmaceutical composition containing a tryptophan derivative |
| 05/29/2013 | EP2595624A2 Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |